- Home
- USLM vs AKRO Comparison
USLM vs AKRO Comparison
Compare USLM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USLM
- AKRO
- Stock Information
- Founded
- USLM 1948
- AKRO 2017
- Country
- USLM United States
- AKRO United States
- Employees
- USLM N/A
- AKRO N/A
- Industry
- USLM Other Metals and Minerals
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- USLM Industrials
- AKRO Health Care
- Exchange
- USLM Nasdaq
- AKRO Nasdaq
- Market Cap
- USLM 2.8B
- AKRO 3.9B
- IPO Year
- USLM N/A
- AKRO 2019
- Fundamental
- Price
- USLM $100.07
- AKRO $54.58
- Analyst Decision
- USLM
- AKRO Strong Buy
- Analyst Count
- USLM 0
- AKRO 6
- Target Price
- USLM N/A
- AKRO $82.50
- AVG Volume (30 Days)
- USLM 207.2K
- AKRO 1.8M
- Earning Date
- USLM 07-30-2025
- AKRO 08-08-2025
- Dividend Yield
- USLM 0.24%
- AKRO N/A
- EPS Growth
- USLM 50.52
- AKRO N/A
- EPS
- USLM 4.20
- AKRO N/A
- Revenue
- USLM $337,287,000.00
- AKRO N/A
- Revenue This Year
- USLM $21.67
- AKRO N/A
- Revenue Next Year
- USLM $13.19
- AKRO N/A
- P/E Ratio
- USLM $23.81
- AKRO N/A
- Revenue Growth
- USLM 17.83
- AKRO N/A
- 52 Week Low
- USLM $65.45
- AKRO $21.02
- 52 Week High
- USLM $159.53
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- USLM 50.26
- AKRO 68.00
- Support Level
- USLM $94.02
- AKRO $53.05
- Resistance Level
- USLM $102.42
- AKRO $56.49
- Average True Range (ATR)
- USLM 3.53
- AKRO 2.44
- MACD
- USLM -0.41
- AKRO -0.26
- Stochastic Oscillator
- USLM 46.61
- AKRO 86.02
About USLM United States Lime & Minerals Inc.
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.